articleThe LancetMay 1, 2002Closed access

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

SBStephen B. HanauerBGBrian G. FeaganGRGary R. LichtensteinLMLloyd MayerSSStefan Schreiber

University of Chicago Medical Center · Western University · +9 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

4,157
total citations
FWCI
78.31
Percentile
100%
References
30
Citations per year

Authors

11

Topics & keywords

Topics
Keywords
  • Medicine
  • Infliximab
  • Crohn's disease
  • Placebo
  • Internal medicine
  • Clinical endpoint
  • Odds ratio
  • Randomized controlled trial
No related works found for this paper.